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Formaldehyde cross-linking of protein complexes combined with immunoprecipitation and mass spectrometry analysis is a
promising technique for analysing protein-protein interactions, including those of transient nature. Here we used integrin β1
as a model to describe the application of formaldehyde cross-linking in detail, particularly focusing on the optimal parameters
for cross-linking, the detection of formaldehyde cross-linked complexes, the utility of antibodies, and the identiﬁcation of binding
partners. Integrin β1 was found in a high molecular weight complex after formaldehyde cross-linking. Eight diﬀerent anti-integrin
β1 antibodies were used for pull-down experiments and no loss in precipitation eﬃciency after cross-linking was observed.
However, two of the antibodies could not precipitate the complex, probably due to hidden epitopes. Formaldehyde cross-linked
complexes, precipitated from Jurkat cells or human platelets and analyzed by mass spectrometry, were found to be composed of
integrin β1, α4a n dα6o rβ1, α6, α2, and α5, respectively.
1.Introduction
Protein-protein interactions are the basis for most cellu-
lar processes, including signalling, protein synthesis, and
metabolism. Detailed knowledge of these protein networks is
required in order to better understand diseases and develop
adequatetreatments.Atpresent,protein-proteininteractions
are commonly investigated by yeast-two-hybrid approaches
[1]a n db yin vitro binding studies [2]. However, these
approaches are prone to false positive identiﬁcations because
they do not take into account the temporal and local separa-
tions that occur in a living system. One tool to study protein-
protein interactions in a physiological context is aﬃnity
enrichment of the protein of interest followed by detec-
tion of its binding partners using either immunodetection
methods or mass spectrometry [3]. However, this classical
immunoprecipitation method has two drawbacks. Weak
interactionscouldbemissed,ifstringentwashconditionsare
applied. In contrast, nonstringent conditions may enable the
identiﬁcation of more proteins, but many of these could be
false positives only binding the bait protein during sample
preparation.
One approach to solve this problem is applying covalent
cross-linking to intact cells and thereby stabilizing protein-
protein interactions, including very weak and transient ones
[3]. After this ﬁxation step, highly stringent conditions can
be used during cell lysis and aﬃnity enrichment, minimizing
the risk of identifying false positives. Several cross-linkers
varying in spacer arm lengths, reaction groups, and other
properties are commercially available. One of the shortest
available cross-linkers is formaldehyde (2.3–2.7 ˚ A), which
has been used for a long time in histology and pathology to
“freeze” the native state of tissues and cells [4]. The exper-
imental conditions used in these applications lead to a very
tightnetworkofcross-links,whichpreventstheprecipitation
of one protein of interest as required for protein-protein
interactionstudies.However,lowerformaldehydeconcentra-
tions (0.4–2% instead of 4%) and especially shorter reaction2 Journal of Biomedicine and Biotechnology
times (minutes instead of hours) allow the utilization of
formaldehyde as a cross-linker to analyze protein-protein
interactions as shown by us and others [5–8].
The application of formaldehyde as a cross-linker has
several advantages. Only closely associated proteins can
be cross-linked due to the small size of formaldehyde.
Furthermore, its high permeability towards cell membranes
enables cross-linking in the intact cell, without addition
of organic solvents such as dimethyl sulfoxide as neces-
sary for other cross-linkers. Formaldehyde is also thought
to allow very fast cross-linking and the stabilization of
transient interactions [4]. Finally, formaldehyde is available
in almost every laboratory at costs that amount to only
a fraction of other cross-linkers. However, formaldehyde
cross-linking is not yet an established standard method
and many questions regarding the optimal experimental
conditions and the usability of antibodies for pull-down of
proteins after formaldehyde treatment remain. For example,
epitopes recognized by antibodies raised against endogenous
proteins could be destroyed by formaldehyde modiﬁcation,
which would prevent their application [9]. Similarly, the
physiological environment of a protein of interest, and
the type and extent of its interactions may also aﬀect the
experimental outcome. Therefore, we decided to investigate
diﬀerent aspects of formaldehyde cross-linking in more
detail using the transmembrane protein integrin β1a sa
model.
Integrins are membrane spanning heterodimeric com-
plexes that play important roles in cell adhesion and
migration processes by interacting with components of
the extracellular matrix [10]. Each integrin heterodimer
is composed of one α and one β subunit, which are
noncovalently associated. 18 α subunits and 8 β subunits
are found in humans, which form 24 diﬀerent heterodimers.
The biggest subgroup with 12 members is formed by β1
containing heterodimers [11]. Before being able to bind a
ligand,integrins havetobeactivatedthroughanintracellular
process termed inside-out signalling. For example, during
platelet activation, thrombin triggers talin activation via a
pathway involving protein kinase C, the small GTPase Rap1
and the Rap1 eﬀector Rap1-interacting molecule (RIAM)
[12]. Activated talin then binds to the intracellular tail of
the integrin and causes conformational change of the two
integrin chains. This allows binding of extracellular ligands,
which drives the cytoplasmic tail of the integrin to bind
additional adaptor proteins, establishes a connection to the
cytoskeleton and leads to the delivery of the external signal
(outside-in signalling).
Several intracellular interaction partners have been
described for integrins, despite the shortness of the intracel-
lular tail of integrins, which varies between 40 and 60 amino
acids.25adaptorproteinshavebeenreportedforintegrinβ1,
including talin, tensin, ﬁlamin and kindlin [13]. However,
these interactions cannot take place simultaneously, but
depend on the activation status of the cell and the integrin.
The detailed binding procedures as well as the signalling
processes triggered by these are not fully understood. For
example, talin and kindlin both interact with integrin β and
a crosstalk between them is assumed. However, it remains
unclear, whether both proteins connect with the integrin at
the same time or binding occurs sequentially [14]. Studying
the interaction partners of integrins using the formaldehyde
cross-linking approach, which should be able to identify
transient and indirect interaction partners of proteins, may
shed more light on these processes and would therefore be
very valuable.
In the present study, we report the optimization of a pro-
tocol applying formaldehyde cross-linking combined with
immunoprecipitation and mass spectrometry (Figure 1(a))
to analyze the interaction network of integrin β1.
2.MaterialsandMethods
2.1.CellsandReagents. Jurkat cells were grown in Dulbecco’s
modiﬁed medium (GIBCO, high glucose) containing 10%
fetal bovine serum (GIBCO), L-glutamine and penicillin/
streptomycin. Human platelets were isolated from healthy
human volunteers as described earlier [15]. This was
approved by the University of British Columbia Research
Ethics Board and informed consent was granted by the
donors. Brieﬂy, whole blood was drawn from the antecubital
vein into 0.15% (v/v) acid-citrate-dextrose anticoagulant.
Platelets were isolated by centrifugation and washed in
physiological buﬀer. All anti-integrin β1 antibodies were
monoclonal mouse anti-human antibodies provided by John
Wilkins (Manitoba). Goat anti-mouse Alexa Fluor 680 was
obtained from Molecular Probes and goat anti-mouse HRP
was received from BioRad.
2.2. Modeling of Integrin β1 Structure. The integrin β1
structure was modeled on the structure of human integrin
β3[ 16] using SWISS MODEL [17, 18] and visualization
was performed using the Swiss-Pdb Viewer Deep View
(http://spdbv.vital-it.ch).
2.3. Formaldehyde Cross-Linking. Formaldehyde solution
was obtained by dissolving 0.4% to 4% paraformaldehyde
(Fisher Scientiﬁc) in PBS for 2 h at ∼80◦C. The solution was
ﬁltered (0.22μm), stored in the dark at RT and discarded
after 4 weeks. For cross-linking, Jurkat cells were pelleted
in a 50ml reaction tube, resuspended in PBS and counted.
Cells were centrifuged again and resuspended to 1 × 107
cells/ml in formaldehyde solution. Cells were incubated
with mild agitation for 7 min at RT and then pelleted at
1800g and RT for 3 min, resulting in 10 minutes exposure
to formaldehyde. The supernatant was removed and the
reaction was quenched with 0.5ml ice-cold 1.25M glycine/
PBS. Cells were transferred to a smaller tube, spun, washed
once in 1.25M glycine/PBS and lysed in 1ml RIPA buﬀer
(50mM Tris HCl, pH 8.0, 150mM sodium chloride, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA,
proteaseinhibitors(Completemini,EDTA-free,RocheDiag-
nostics)) per 1 × 108 cells for 60 minute on ice. After 30
minutes, cell lysates were treated with 50 strokes using a
Dounce homogenizer. Lysates were spun for 30 minutes at
20000gand4◦Ctoremoveinsolubledebris.Thesupernatant
was either used directly or stored at −80◦C. Control cellsJournal of Biomedicine and Biotechnology 3
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Figure 1: Formaldehyde cross-linking. (a) Workﬂow of formaldehyde cross-linking. Cells are treated with formaldehyde, lysed and
protein complexes (oval shapes) are precipitated by antibodies (y-shaped). Cross-links are indicated by black triangles. Only antibodies,
whose epitopes are not destroyed during formaldehyde modiﬁcation, can precipitate the complex. (b) Reaction scheme of formaldehyde
modiﬁcation, cross-linking and cross-linking reversal. (c) and (d) Formaldehyde derived cross-links are preserved, if samples are only
incubated at 65
◦C, whereas most of the cross-links are reversed at 99
◦C. (c) Schematic model. Proteins are depicted as oval shapes,
formaldehyde cross-links as black triangles. (d) Anti-integrin β1 immunoblot analysis of cross-linked Jurkat cells (JB1A, anti-mouse HRP).
were treated exactly the same way, except that they were
resuspended in PBS instead of formaldehyde solution. When
platelets were used for cross-linking, ∼ 1.5 × 109 cells were
resuspended in 10 ml formaldehyde solution and lysed in
1m lR I P Ab u ﬀer.
2.4. Immunoprecipitation, Western Blot Analysis and Silver
Staining of SDS PAGE. Protein concentration was deter-
mined using a BCA assay (Pierce). The indicated amounts
of antibodies and lysates were incubated for 1 h, after that
10 to 25μl protein G agarose beads (Immobilized Protein G,
Pierce)wereaddedandimmunoprecipitationwasperformed
overnight. All steps were performed with mild agitation at
4◦C. For mass spectrometric analysis, lysates were precleared
by incubation with the same amount of beads for 2 h
before the antibody was added. The supernatants of the
immunoprecipitations were kept for analysis and the beads
were washed either twice with PBS for western blot analysis
o rt h r e et i m e sw i t hR I P Ab u ﬀer for mass spectrometric
analysis. 4x reducing SDS Loading Dye (500mM Tris HCl,
pH 6.8, 8% SDS, 40% glycerine, 20% β-mercaptoethanol,
5mg/ml bromophenol blue) was added to the beads as well
as to the lysates and the supernatants and samples were
incubated at either 65
◦Co r9 9
◦C for 5 min or 10–20 min,
respectively, before they were separated by SDS PAGE using
a 8% Laemmli gel [19]. For western blot analysis, proteins
were transferred via a semi-dry procedure on polyvinylidene
diﬂuoride membranes (Pall Corporation), blocked for 1 h
at RT with 5% milk powder in PBST (PBS, 0.1% Tween4 Journal of Biomedicine and Biotechnology
20) and incubated with JB1A (0.1μg/ml) overnight at 4◦C.
Membranes were either incubated with anti-mouse HRP
or anti-mouse Alexa Fluor 680 (both 1:10000) for 1 h
at RT. Membranes treated with anti-mouse Alexa Fluor
680 were scanned with a ﬂuorescence scanner (Odyssey,
LICOR) using excitation/emission wavelengths of 700 and
800nm, whereas signals on anti-mouse HRP incubated
membranes were detected with chemiluminescence solution
(ECL, GE Healthcare). Quantitation of immunoblot analysis
wasperformedusingthesoftwareImageJ[20].Silverstaining
was performed using a modiﬁed protocol of Gharahdaghi et
al. [21]. Brieﬂy, gels were ﬁxed with 10% acetic acid/10%
methanol, washed with water and sensitized with 1μg/ml
dithiothreitol for 15 min. Gels were incubated in 0.1% (w/v)
silver nitrate for 15 min and developed with 0.02% (w/v)
paraformaldehyde in 3% (w/v) potassium carbonate until
the desired staining had occurred. The reaction was stopped
by addition of acetic acid.
2.5. In Gel Digestion and LC-MS/MS Analysis. Bands of
interest in silver-stained gels were excised and destained
as described [21]. Brieﬂy, gel bands were incubated in
a freshly prepared destaining solution (15mM potassium
ferricyanide/50mM sodium thiosulfate) until the colour dis-
appeared, washed several times with water and ammonium
bicarbonate (pH 8.0) and chopped in smaller pieces. In-gel
digestion was performed using standard procedures [22].
Brieﬂy, samples were reduced with dithiothreitol, alkylated
with iodoacetamide and digested with trypsin (Promega) in
ammonium bicarbonate overnight. Peptides were extracted
twice from the gel pieces, dried down in a vacuum cen-
trifuge, reconstituted in 5% formic acid and STAGE-tip
puriﬁed [23]. Separation and identiﬁcation of peptides was
performed by nano-HPLC MS/MS on an Agilent 1100
(Agilent, Santa Clara, CA) coupled to an FT-ICR (LTQ-
FT, Thermo Electron Corporation, Waltham, MA) using a
15cm long, 75μm I.D. fused silica column packed with
3μm particle size reverse phase (C18) beads (Dr. Maisch
GmbH, Germany) with water:acetonitrile:formic acid as the
mobile phase with gradient elution. Proteins were identiﬁed
by extracting the Mascot generic format (MGF) ﬁles from
the MS data using DTA Super Charge (part of the MSQuant
open source project (http://msquant.sourceforge.net/)) and
searching them against the ENSEMBL database with the
X!Tandem algorithm embedded in the Global Proteome
Machine (http://www.thegpm.org/). The protein expect
score (log(e)) indicates the probability of false assignment of
a protein: log(e) = −1 equates to a 1 in 10, log(2) = −2t oa
1 in 100 chance of a stochastic protein assignment. Known
contaminants such as keratin were removed from the protein
lists.
3. Results andDiscussion
3.1. Formaldehyde Cross-Linking Conditions. The usage of
formaldehyde as cross-linking reagent has to be evaluated
in order to determine the optimal balance between highest
yield of complex formation and lowest artefact generation
[4]. Optimization has to be performed for each protein of
interest, as it is dependent on the physiological environment
oftheproteinitselfandcanvaryforexamplebetweencytoso-
lic and membrane proteins. Three main parameters play a
critical role during formaldehyde cross-linking: the reaction
temperature,theincubationtimeandtheformaldehydecon-
centration.Thetemperaturedependencyhadbeenstudiedin
our laboratory earlier and a diﬀerence between incubation at
37
◦Ca n d2 5
◦C could not be detected (unpublished results).
Room temperature is advantageous, as it results in the
most convenient and easiest approach possible. In addition,
we chose not to increase the incubation time to more
than 10 minutes, as the advantage of using formaldehyde
as a cross-linker is the short reaction time it requires,
which minimizes the formation of unspeciﬁc cross-links
and allows the ﬁxation of transient interactions. Moreover,
model studies on peptides had shown that incubation time
and formaldehyde concentration are complementary [24].
Therefore, we decided to limit our study to the usage of
diﬀerent concentrations of formaldehyde in terms of our
model protein integrin β1c o m p l e x .
Jurkat cells were chosen for studying integrin β1 interac-
tions,asthishumanTcelllineexpresseshighamountsofthis
integrin and has been used extensively for its investigation
before [25]. Diﬀerent concentrations of formaldehyde (0.4%
to 2%) were used to cross-link Jurkat cells. The lowest
concentration was chosen as it had been shown earlier to
result in the best protein loss/cross-linking yield balance [4],
thehighestwastwiceashighasformaldehydeconcentrations
shown to be successful earlier [5]. Cells were lysed under
stringent conditions using RIPA buﬀer to destroy weak
and noncovalent interactions, and protein amounts were
determined. Lysates of formaldehyde treated cells contained
lower amounts of protein than nontreated cells. This can
be explained by the formation of insoluble complexes, for
example, nuclear proteins being cross-linked to DNA, which
were precipitated during lysis and removed in the insoluble
pellet. This eﬀect was visible during sample generation: lysis
of nontreated cells using the stringent RIPA buﬀer led to
the release of DNA, which formed a cloudy precipitate and
could be easily removed. In contrast, a cloudy suspension
w a sg e n e r a t e dd u r i n gl y s i so ff o r m a l d e h y d et r e a t e dc e l l sa n d
thepellethadadiﬀerentconsistency,whichrequiredalonger
centrifugation period to become separated. Consistent with
this observation, nuclear proteins were not detected in the
lysatebyimmunoblotanalysis.However,membraneproteins
were overrepresented due the loss of nuclear proteins
(data not shown). We recommend using this diﬀerence in
appearance as an early indication of successful cross-linking.
3.2. Detection of Formaldehyde Cross-Linked Integrin β1
Complexes. Optimization of the formaldehyde cross-linking
protocol involving integrin β1 required a read-out of the
cross-linking eﬃciency, for example, the detection of a
complex containing the integrin. Formaldehyde cross-links
are reversible during the standard sample preparation for
S D SP A G Ea n a l y s i s( Figure 1(b)), which includes boiling in
reducing Laemmli buﬀer [19], thus cross-linked complexesJournal of Biomedicine and Biotechnology 5
would not be detected under these conditions [8]. How-
ever, by reducing the incubation temperature to 65
◦C,
cross-linked complexes are not fully destroyed and remain
detectable(Figure 1(c))[5].Membraneproteinstudiesbygel
electrophoresis are often performed at even lower temper-
atures (37–40◦C). Initial immunoprecipitation experiments
we had performed indicated that at 37
◦C the antibodies
used for pull-downs would not dissociate into their heavy
and light chains (data not shown). Instead, during gel elec-
trophoresis the intact antibodies would migrate at molecular
weights that would overlap with the cross-linked complexes
and therefore interfere with their detection. Consequently,
we decided not to use temperatures lower than 65
◦Ci no u r
experiments.
Jurkat cells treated with 2% formaldehyde were used
to conﬁrm the detection of cross-linked complexes. Lysates
were incubated at 65
◦Ca n d9 9
◦C, respectively and analyzed
by western blot using the antibody JB1A, which had been
used for detection of integrin β1 in earlier studies [26].
We could recognize a higher molecular weight complex
containing integrin β1 in samples treated for 5 min at
65
◦C, whereas this band was nearly undetectable after
boiling for 10 minutes at 99
◦C( Figure 1(d)). Therefore, we
concluded that we were visualizing a cross-linked complex
containing integrin β1. However, integrin β1 was also found
in the monomeric form at appr. 150kDa after incubation
at 65
◦C. This could be due to incomplete cross-linking, as
the conditions applied during formaldehyde cross-linking
do not lead to a high extent of protein cross-linking,
leaving a large fraction of integrin β1 noncross-linked.
Alternatively, incubation at 65
◦C may lead to partial reversal
of formaldehyde cross-links and release of integrin β1e v e n
at a lower temperature.
3.3. Balance of Cross-Linking Eﬃciency and Protein Loss.
Equal amount of lysates of the samples generated using
diﬀerent concentrations of formaldehyde were analyzed by
immunoblotting (Figure 2(a)). No complex was detected
in the control, in which cells were treated under cross-
linking conditions but without formaldehyde. With 0.4%
formaldehyde, a small amount of complex was detected,
which increased with higher formaldehyde concentrations.
At 0.8% formaldehyde, much more complex was visible.
The amount increased slightly at higher concentrations of
formaldehyde, but then settled, with no apparent diﬀerence
between 1.2 and 2%. The signal intensities of monomeric
integrin β1 and the complex were quantiﬁed, the values at
2% formaldehyde were set to 100% and relative intensities
were calculated. These were plotted together with the total
protein concentrations of the lysates to determine the
optimal cross-linking parameters (Figure 2(b)). The amount
of monomeric integrin β1 did not vary signiﬁcantly between
the diﬀerent formaldehyde concentrations, even though the
amount of the complex was increasing (Figure 2(b)). This
apparent contradiction can be explained by the aforemen-
tioned observation that membrane proteins are enriched
during formaldehyde treatment relative to other cellular
components. Thus, by loading equal total protein amounts
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Figure 2: Optimization of formaldehyde concentration. Jurkat
cells were treated with diﬀerent concentrations of formaldehyde
(PFA), lysed and the cell lysates were analyzed. (a) Anti-integrin β1
immunoblot of lysates (JB1A, anti-mouse HRP). (b) Western Blot
results were quantiﬁed using ImageJ. Values obtained at 2% PFA
were set to 100% and relative intensities were calculated. Protein
concentration of the lysates had been determined using a BCA
assay. Total protein concentrations and relative signal intensities of
the western blot analysis were plotted in one graph to show the
correlation between the parameters.
in each lane, increasingly higher amounts of total integrin
β1 were applied. Unfortunately, this variation cannot be
compensated using loading controls, as the exact amount
of each cross-linked protein cannot be predicted. The
decrease in protein concentration due to formaldehyde
modiﬁcation was most pronounced between 0% and 0.4%
formaldehyde treatment, increased at 0.8% but stabilized
at higher formaldehyde concentrations (Figure 2(b)). Com-
paring the loss of protein to the gain of integrin β1
complex (Figure 2(b)) implied that using a formaldehyde
concentration between 1 and 2% should lead to the best
cross-linking eﬃciency/protein loss balance, without major
diﬀerences in this range. However, increasing the extent
of cross-linking may also result in the formation of larger
complexes by involving proteins that do not directly bind
to integrin β1, including the cytoskeleton. This would
lead to the formation of more extensive, heterogeneous6 Journal of Biomedicine and Biotechnology
Table 1: Monoclonal anti-integrin β1 antibodies used in this study.
Antibody Activity Epitope location Reference
JB1B Stimulatory Continuous (AA 671-705) Wilkins et al. [26]
JB1A Inhibitory Continuous (AA 82-87) Ni and Wilkins [28]
B3B11 Stimulatory Continuous (AA 660-668) Wilkins et al. [26]
N29 Stimulatory Continuous (AA 14-55) Ni and Wilkins [29]
B44 Stimulatory Probably continuous/Diﬀ. Region than N29 and JB1B/B3B11 Wilkins et al. [26]
6S6 — —
3S3 Inhibitory Probably discontinuous Gao et al. [30]
21C8 Stimulatory Discontinuous near JB1B/B3B11 Wilkins et al. [26]
cross-linked complexes that would provide a larger surface
to which nonspeciﬁc proteins can bind during sample
processing. As a result, an increasing amount of abundant
cytoskeletal proteins and common contaminants would be
identiﬁed that would not be considered speciﬁc interactors.
Therefore, to minimize such apparent artefact generation,
we decided to perform the following investigations using
more stringent conditions by applying 0.4% formaldehyde.
This increases the likelihood of missed identiﬁcations of
speciﬁc interactors of low abundance and of interactions
of low stoichiometry. Even though higher formaldehyde
concentrations would counter this eﬀect, they would also
result in more artefacts, hence diﬀerential analysis using
multiple formaldehyde concentrations would still not be
able to distinguish between speciﬁc interactors and artefacts.
Instead, individual follow-up experiments for each identiﬁed
protein would be required to determine its speciﬁcity. As
the focus of this study was not to obtain an extensive
list of putative interactors, but rather to demonstrate
the general validity of the approach, we chose lower
formaldehyde concentrations and high stringency. Users
interested in maximizing the number of captured proteins
should consider using higher formaldehyde concentrations
instead.
3.4.AnalysisofAnti-Integrinβ1Antibodies. Studyinginterac-
tion partners using formaldehyde cross-linking and aﬃnity
puriﬁcation requires the antibody to still recognize its
target after reaction with formaldehyde. In our earlier
studies utilizing myc-tagged proteins, the antibody 9E10
was shown to be suitable for formaldehyde treatment, as
it still precipitated protein complexes [5]. However, this
h a st ob ep r o v e nf o re v e r ya n t i b o d y / a n t i g e np a i rb e f o r ei t
can be used for interaction studies involving cross-linking.
The use of a tagged, exogenous version of integrin β1
would result in additional risks coming with this approach,
such as identiﬁcation of false positives binding to the tag,
altered protein localization, or general changes in the protein
environment due to elevated expression levels. Antibodies
recognizing the endogenous protein are required to exclude
these inﬂuences. Not all monoclonal antibodies are expected
to be suitable in this technique, as some epitopes might
be destroyed by formaldehyde modiﬁcation of amino acids
(Figure 1(a)).
We wondered whether it is possible to predict the
applicability of an antibody in the formaldehyde cross-
linking approach. Therefore, we analyzed eight diﬀerent and
mostly well studied monoclonal anti-integrin β1 antibodies
(Table 1 and Figure 3). First we wanted to know whether
these antibodies were able to immunoprecipitate integrin
β1 from cell lysates generated using the lysis conditions
we apply during cross-linking. All antibodies were tested
for aﬃnity puriﬁcation and were found to precipitate two
integrin β1 bands between 100 and 150kDa from Jurkat
cell lysates (Figure 3(a)). These two bands likely represent
two diﬀerently N-glycosylated integrin β1 chains that have
been detected on the cell surface of several cell types [27]. In
contrast to our results, Meng et al could not detect the low-
mass integrin β1 in Jurkat cells, but they only investigated
the cell membrane whereas we precipitated integrin β1f r o m
whole cell lysates. This suggests that the low-mass form may
be retained in the endoplasmatic reticulum.
A closer look at the known properties of the anti-integrin
β1 antibodies revealed that ﬁve of them had been shown
to stimulate integrins when added to living cells, while two
showed inhibitory character (Table 1). However, as we were
planningtousetheseantibodiesforprecipitationofintegrins
from cross-linked and thereby ﬁxed cells, these properties
should not aﬀect our experiments. More importantly, the
epitopes of some of these antibodies are known and located
at very diﬀerent positions in the extracellular part of the
protein: N29 and JB1A detect continuous peptide sequences
close to the protein N-terminus (Figure 3(b)). In contrast,
B3B11 and JB1B detect continuous sequences at the opposite
end of the extracellular part of integrin β1( Figure 3(b)),
where also the discontinuous epitope of 2C18 is found [29].
B44 is known to recognize a diﬀerent part of the protein
thantheotherantibodiesbutthepreciseepitopeisunknown.
Since the B44 antibody is working in immunoblotting
experiments, its epitope is expected to be composed of a
continuous sequence [26]. In contrast, 3S3 cannot be used
for immunoblotting indicating a discontinuous epitope.
Wefurthermodelledtheintegrinβ1structureonintegrin
β3 to gain insight into the three-dimensional location of the
known epitopes (Figure 3(c)). As expected the epitopes are
located in very diﬀerent parts of the protein. Additionally
it is known that the epitopes of N29 and B44 are hidden
in the inactivated form of integrin β1a so ns o m ec e l l
lines they can only detect the receptor after it had becomeJournal of Biomedicine and Biotechnology 7
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Figure 3:Analysisofanti-integrinβ1antibodies.(a)Testofantibodiesforimmunoprecipitation.0.5mgJurkatcelllysatewasincubatedwith
1μgoftheindicatedantibodyandaﬃnitypuriﬁcationwasperformed.PrecipitationswereanalyzedbyJB1Aimmunoblot(anti-mouseHRP).
Two integrin β1 chains were detected in all immunoprecipitations. The heavy (HC) and light chains (LC) of the antibodies are indicated. (b)
Amino acid sequence of the extracellular domain of human integrin β1. Known continuous epitopes are indicated. Underlined amino acids
are known to become formaldehyde modiﬁed ﬁrst. (c) Model of the extracellular part of human integrin β1 ,b a s e do nt h ec r y s t a ls t r u c t u r e
of Integrin β3( Swiss Model). Indicated are the same epitopes as in (b).
activated [29]. To assess whether the antibodies would also
beabletoworkafterformaldehydetreatment,wehadacloser
look at the epitope sequences, which are known for four
of them (Figure 3(b)). It had been shown that the amino
acids, which are formaldehyde-modiﬁed ﬁrst during the
short incubation times used under cross-linking conditions,
arelysine, cysteineand tryptophan [24]. The epitopes of N29
and JB1A are composed to a higher extent of these amino
acids(20and30%),comparedto7%and12%forB3B11and
JB1B, suggesting that N29 and JB1A are less likely to work
after formaldehyde treatment.
3.5. Precipitation of Formaldehyde Generated Integrin β1 Con-
taining Complex. Our next step was to determine whether
the antibodies found to precipitate integrin β1 in the
previous section can detect and pull down the integrin β1
complex. Jurkat cells were treated with or without 0.4%
formaldehyde. Cells were lysed and the lysates were used
for an immunoprecipitation using the antibody JB1B and a
control pull-down which was performed without an anti-
body (Figure 4(a)). The higher molecular weight complex
containing integrin β1 was only detected in formaldehyde
treated cells and was only precipitated when the antibody
was added. No complex was detected in the supernatant
of the immunoprecipitation, indicating its complete pull-
down. Furthermore, no loss in total integrin β1 precipitation
was observed, indicating that formaldehyde treatment did
not destroy the JB1B epitope. This had been expected, as
the epitope does not contain many of the easily modiﬁable
amino acids.8 Journal of Biomedicine and Biotechnology
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Figure 4: Precipitation of cross-linked integrin β1 complexes. (a, b) Jurkat cells were treated with or without 0.4% formaldehyde (PFA)
before lysis. Immunoprecipitation was performed using 0.5mg of lysate and 1μg of the indicated antibody. Immunoprecipitations (IP) and
supernatants (SN) were analyzed for presence of integrin β1 complexes using JB1A for immunoblotting (anti-mouse Alexa Fluor 680). (a)
JB1B precipitated the integrin β1 complex (indicated by arrow) from formaldehyde treated cells. (b) Test of the remaining seven antibodies
forprecipitationofintegrinβ1fromformaldehydetreatedcellsusingthesameparametersasin(a).(c)Jurkatcellsweretreatedwithdiﬀerent
concentrations of formaldehyde (PFA) and lysed. 100μg lysate were used for pull-downs with JB1B (1μg) and immunoprecipitations (IP)
and supernatants (SN) were analyzed by anti-integrin β1 immunoblotting (JB1A, anti-mouse HRP).
As a next step, all of the other antibodies were used to
precipitate integrin β1 from formaldehyde treated and non-
treated Jurkat cells (Figure 4(b)) .A l lo ft h e mw e r ea b l et o
precipitate the target protein even after formaldehyde treat-
ment, indicating that none of their epitopes was destroyed in
such a way that it would prevent precipitation. Even for N29
and JB1A, whose epitopes contain a high percentage of easily
modiﬁable amino acids, no fundamental loss in integrin β1
precipitation was observed. However, not all antibodies were
equally able to precipitate integrin β1 containing complexes:
B3B11, JB1A and 3S3 precipitated the complex completely,
since no integrin β1 was detected in the high molecular
range of the supernatant. Only partial precipitation of a high
molecularweightcomplexwasobservedusingtheantibodies
2C18 and 6S6, where part of the complex was detected
in the supernatant of the precipitation. No precipitated
complex was detected using the antibodies N29 and B44.
As these antibodies were able to precipitate integrin β1o f
formaldehyde treated cells, it is unlikely that their epitopes
were destroyed during the process. However, as mentioned
earlier N29 and B44 have both been shown to detect
activated integrin β1 on cells, whereas their epitopes are
disguised on non-activated cells [29]. Stringent lysis of cells
destroys this conformational limitation and allows detection
by the antibodies. In contrast, cross-linking preserves the
conformation and therefore a non-activated complex wouldJournal of Biomedicine and Biotechnology 9
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Figure 5: Analysis of integrin β1 complexes (CL) from Jurkat cells and human platelets. (a) Jurkat cells were treated with or without 0.4%
formaldehyde (PFA) before lysis. Immunoprecipitation was performed using 2mg lysate and 5μg of JB1B and analyzed by SDS PAGE. The
indicated area was excised and analyzed by mass spectrometry. (b) Anti-integrin β1 immunoblot (JB1A, anti-mouse Alexa Fluor 680) of
JB1B pull-downs performed on human platelets treated with and without 0.4% formaldehyde (PFA). 100μg platelet lysate and 0.85mg JB1B
were used. Complexes containing integrin β1 are indicated by the arrow. (c) SDS PAGE analysis of JB1B immunoprecipitates from noncross-
linked and cross-linked human platelets. Immunoprecipitation was performed using 0.7mg lysate and 4.25μg JB1B. The indicated band was
excised and examined with mass spectrometry.
beundetectableandnotprecipitatedbythesetwoantibodies.
On the other hand, they could be able to precipitate an
activated complex which in turn would not be recognized
by some of the other monoclonal antibodies. This limitation
of antibody usage does not only apply to formaldehyde
cross-linking, but restricts every approach where protein
complexes are precipitated by antibodies, including the tra-
ditional coimmunoprecipitation method which uses gentle
lysis conditions to preserve protein interactions.
Finally we asked whether a higher degree of modiﬁcation
induced by higher concentrations of formaldehyde would
impede the precipitation of integrin β1 using the antibody
JB1B. Therefore we tested the ability of JB1B to pull
down complexes from cell lysates, which were obtained
after treatment of Jurkat cells with varying formaldehyde
concentrations. JB1B was able to precipitate integrin β1a n d
the complex regardless of the formaldehyde concentrations
applied, which was shown by analysis of the pull-downs
as well as the supernatants of the immunoprecipitations
(Figure 4(c)): no protein was detected in the supernatants,
whereas integrin β1 was detected in the range of the
monomeric protein and the high molecular weight complex
in the immunoprecipitations. We concluded that JB1B is the
most universal of the anti-integrin β1 antibodies we had
tested, and therefore the most useful for formaldehyde cross-
linking.
3.6. Mass Spectrometric Analysis of Complexes Containing
Integrin β1. Western blot analysis had shown that we
precipitate a high molecular weight complex containing
integrin β1 after formaldehyde treatment. As the other
components of this complex were unknown to us, we used
massspectrometrytoidentifythem.Theintegrinβ1complex
was precipitated by JB1B, separated by SDS PAGE and
visualizedbysilverstaining(Figure 5(a)).Theindicatedband
was excised, in gel digested and analyzed by LC-MS/MS.
Using Jurkat cells we performed this experiment in several
independent repeats, and detected integrin β1i ne v e r y
sample (Table S1). Furthermore we consistently identiﬁed
integrin α4. The receptor formed by these integrins is VLA-4
(very late antigen 4), a known receptor found on T cells [31]
and a high abundant integrin on Jurkat cells [25].
Two of these experiments also allowed the identiﬁcation
of additional proteins (Table 2). The listed proteins were
not detected in control experiments using either non-
formaldehyde treated cells or immunoprecipitations per-
formed without the antibody when analysing gel bands at
massescorrespondingtotheintegrinβ1containingcomplex.
Of these additionally identiﬁed proteins, integrin α6i s
known to form a receptor termed VLA-6 together with
integrin β1 on T cells, which has not been detected in Jurkat
cells before [25]. Two additional integrin α subunits were
detected only in dataset 2: integrin α5( l o g ( e )= −36.4) and
α1( l o g ( e )= −1.7). Integrin α5h a db e e nd e m o n s t r a t e dt o
be expressed together with integrin β1 on Jurkat cells [25],
whereas integrin α1 is known to form a collagen-recognizing
receptor with integrin β1 on endothelial cells [32]. Even
though only few peptides of each protein were sequenced,
the identiﬁcation of the integrin α s u b u n i t si sr e l i a b l ea st h e y
do not share high homologues sequences and all sequenced
peptides were unique for each integrin α.
The other identiﬁed proteins are not known to inter-
act directly with integrin β1[ 13] .A sam e m b e ro ft h e
cytoskeleton, actin is intertwined with integrin function
and associated with integrins through adaptor proteins such
as talin [10]. However, an adaptor was not consistently
identiﬁed in these immunoprecipitations. Furthermore actin10 Journal of Biomedicine and Biotechnology
Table 2: Proteins identiﬁed in the integrin β1 complex precipitated from Jurkat cells. Formaldehyde cross-linked Jurkat cell lysate was used
to enrich integrin β1 with JB1B. The integrin β1 complex was identiﬁed by SDS PAGE analysis and studied by LC-MS/MS and the GPM.
Only proteins with a log(e) < −1 and which were identiﬁed in both datasets and not in control samples are listed.
Protein Accession Mr [kDa] log(e) (Dataset 1) log(e) (Dataset 2)
Integrin β1 ITGB1 ENSP00000303351 88.4 −39.8 −118.3
Actin, cytoplasmic 2 ACTG1 ENSP00000331514 41.8 −23.4 −73.1
Desmoglein-1 DSG1 ENSP00000257192 113.7 −16.4 −42.9
Filaggrin-2 FLG2 ENSP00000373370 247.9 −15.6 −40.1
Glyceraldehyde-3-phosphate dehydrogenase GAPDHL6 ENSP00000229239 36 −7.4 −18.2
Arginase-1 ARG1 ENSP00000349446 35.6 −7.3 −15.1
Junction plakoglobin JUP ENSP00000377507 81.7 −6 −7
Integrin α4 ITGA4 ENSP00000380227 114.8 −5.1 −6.3
Heat shock protein HSP 90α HSP90AA2 ENSP00000216281 84.6 −2.9 −4.5
C1orf68 C1orf68 ENSP00000354769 26.2 −2.1 −3.2
Integrin α6 ITGA6 ENSP00000264106 126.5 −1.6 −2.4
is a highly abundant protein and its identiﬁcation has to
be judged carefully. The same is true for GAPDH and
heat shock protein HSP 90α, which are both abundant
proteins and frequently found in immunoprecipitations.
Thus we cannot exclude that these proteins are non-speciﬁc
background, even though they were not detected in the
control samples. As formaldehyde cross-linking could also
occur with abundant proteins that colocalize but have lower
binding aﬃnity to integrin β1, this may explain the presence
of abundant proteins. Alternatively, proteins that do not
colocalizebutshowmediumtohighaﬃnitymayformanon-
cross-linked complex in the lysate that is suﬃciently stable
not to be destroyed by the incubation temperature of 65
◦C
that is applied prior to gel separation. This scenario may
also be true for most of the other proteins (Desmoglein-1,
Filaggrin-2, Junction plakoglobin and C1orf68), which are
highly expressed in skin cells. These could be contaminants
similar to keratins (which were removed before data inter-
pretation) occurring during sample preparation. The last
identiﬁedproteinarginase-1isfoundintheliverandplaysan
important role in arginine metabolism [33], a connection to
integrin β1 is not known. On the other hand, formaldehyde
cross-linking would also stabilize interactions between two
proteins that do not directly interact but have a common
binding partner. Therefore, such unexpected ﬁndings may
still provide valuable information.
No known adaptor proteins like talin or tensin were
consistently detected in the complex. This indicates that the
precipitated complex is mostly in an inactive state, where the
two integrin chains form a stable and very compact complex
and no adaptor proteins are bound to the intracellular tail.
This matches our earlier observation that N29 and B44,
which were shown to be unable to detect inactive integrin
β1, did not precipitate this complex. However, talin-1 was
identiﬁed with high conﬁdence (log(e) = −94.9) in one
experiment (dataset 2) indicating the ability to precipitate
integrinβ1/adaptorcomplexesusingourapproach,provided
the integrin β1 on Jurkat cells is activated. All our results
imply that most of the integrin β1 found on the Jurkat cells
is not activated, which is in contrast to an earlier study where
Jurkat cells have been shown to express constitutively active
integrin β1[ 25]. However, it has to be considered that cell
lines change their behaviour over time, thus it might be that
the Jurkat cells used by them and by us diﬀer in this aspect.
3.7. Detection and Analysis of Integrin β1 Complexes in
Human Platelets. In addition to our studies using Jurkat
cells, we wanted to apply our approach also to a diﬀerent
and physiologically more relevant system, and therefore used
human platelets. Platelets express high amounts of integrins,
which play an important role in platelet aggregation. Even
though integrin β1 is not the most abundant integrin found
on platelets, it forms three diﬀerent receptors (α2β1, α5β1,
α6β1) and is involved in platelet adhesion [34].
Human platelets were treated with and without
formaldehyde and the antibody JB1B was used to precipitate
integrin β1 from the lysates. In addition to the monomeric
protein, a high molecular weight complex was detected in
immunoblotting experiments, which was only visible after
formaldehyde treatment (Figure 5(b)). We identiﬁed the
contents of the complex precipitated by JB1B from human
platelets by mass spectrometry (Figure 5(c),T a b l e S 2 ) .
Proteins identiﬁed in two independent experiments are
listed in Table 3.I n t e g r i nβ1 was detected in both pull-
downs as expected. Furthermore, the integrins α6a n dα2,
which are known to form heterodimers with integrin β1o n
platelets, were identiﬁed [34]. Thrombospondin-1, a known
ligand of the integrin receptor α6β1, was also detected in the
integrin β1 complex. As thrombospondin-1 is also the most
abundant protein found in the α-granules of platelets [35],
its identiﬁcation may be merely due to its high abundance
in the platelet lysate. Similarly, integrin αIIb does not form
a heterodimer with integrin β1, but together with integrin
β3 forms glycoprotein IIb/IIIa, the most abundant platelet
receptor. Integrin β3 was only detected in dataset 2 (log(e)
= −40.2), however, the presence of both of these proteins
could be solely due to their high presence in the platelet
lysate as well. On the other hand we cannot exclude that
integrin β1 interacts with one or both of these integrins
forming multi-heterodimers.Journal of Biomedicine and Biotechnology 11
Table 3: Proteins identiﬁed in the integrin β1 complex precipitated from human platelets. Integrin β1 was precipitated by JB1B from
formaldehyde cross-linked platelets. The integrin β1 complexes were identiﬁed by SDS PAGE analysis and investigated by LC-MS/MS and
the GPM. Only proteins with a log(e) < −2 and which were identiﬁed in both datasets are listed. ∗Two diﬀerent isoforms were detected in
the experiments.
Protein Accession Mr [kDa] log(e) (Dataset 1) log(e) (Dataset 2)
Thrombospondin-1 THBS1 ENSP00000260356 129.3 −46.2 −140.1
Integrin α6∗ ITGA6 ENSP00000264106/ 126.5/124 −38.2 −299
ENSP00000364369
Integrin β1 ITGB1 ENSP00000303351 88.4 −29.8 −201.1
Immunoglobulin heavy IGHV4-31 ENSP00000374990 43.9 −9.6 −10
chain C
Hornerin HRNR ENSP00000357791 282.2 −9.4 −20.2
Integrin α2 ITGA2 ENSP00000296585 129.2 −3.4 −144.5
Integrin αIIb ITGA2B ENSP00000262407 113.3 −2.8 −22.8
Filaggrin-2 FLG2 ENSP00000373370 247.9 −4 −4.5
Table 4: Integrin β1 heterodimers detected in Jurkat cells and
human platelets. ∗Only detected in one dataset.
Detected in Integrin heterodimers Ligands
Jurkat cells
β1α4 (VLA-4) Fibronectin, VCAM-1
β1α6 (VLA-6) Laminins
β1α5( V L A - 5 ) ∗ Fibronectin
β1α1∗ Collagens
Human platelets
β1α6 (VLA-6) Laminins
β1α2 Collagens
β1α5( V L A - 5 ) ∗ Fibronectin
The identiﬁcation of immunoglobulin heavy chain C
is assumingly due to the immunoprecipitation, whereas
hornerin and ﬁlaggrin-2 are both proteins expressed in
the skin and could be contaminants caused during sample
preparation. Three proteins which are known to interact
with integrin β1 were only detected in dataset 2: integrin
α5( l o g ( e )= −1.8), talin-1 (log(e) = −142.2) and kindlin-
3( l o g ( e )= −18.5). Integrin α5 is known to form the
receptor VLA-5 with integrin β1. With the detection of this
α chain, we identiﬁed all known integrin β1 containing
heterodimers on platelets. The identiﬁcation of the adaptors
talin-1 and kindlin-3 indicates again that we are able to
precipitate integrin β1/adaptor protein complexes. However,
these experiments were performed on platelets which were
not intentionally stimulated, thus we do not expect high
amounts of activated integrin β1 on these cells. Stimulation
can nonetheless occur to a low degree during platelet
preparation, which explains the detection of talin-1 and
kindlin-3 in one of the samples.
4. Conclusion
Using the transmembrane integrin β1c o m p l e xa sam o d e l ,
our study addressed several critical factors in the formalde-
hyde cross-linking procedure and provides a practical guide
to the optimization of such experiments.
By modifying SDS PAGE sample preparation conditions,
we could detect an additional formaldehyde generated,
high-molecular weight band containing integrin β1b y
immunoblot analysis. LC-MS/MS analysis showed that this
complex was mainly composed of integrins. Several integrin
α subunits known to form heterodimers with integrin β1
could be detected in two diﬀerent systems, Jurkat cells and
human platelets (Table 4). The appearance of a broad band
on the type of gel we had chosen did not provide any
insights into heterogeneity and molecular weight of the
corresponding integrin complex(es). Indeed, the band could
have arisen from a single, multi-integrin complex containing
all of the identiﬁed proteins, albeit the presence of several
distinctcomplexeswithsimilarmolecularweightresultingin
overlapping bands is more likely. Targeted experiments will
be necessary to unequivocally answer this question.
One major focus of this study was to systematically test
the applicability of monoclonal antibodies in precipitating
formaldehyde treated endogenous, nontagged proteins. Two
out of eight antibodies were expected to be less likely to work
in precipitating integrin β1 from formaldehyde treated cells,
since their epitopes contained amino acids that are known to
be susceptible to formaldehyde modiﬁcation [24]. However,
wecouldnotdetectanydiﬀerenceinprecipitation,indicating
that destruction of epitopes is not an overwhelming problem
in the formaldehyde cross-linking procedure at least for the
panel of antibodies we had tested.
Two antibodies, which had been shown before to recog-
nize only activated integrin β1[ 29], did not pull-down the
complex probably due to hidden epitopes in the complex.
This ﬁnding, together with the observation that the analyzed
complexes were mainly composed of integrin α and β
chains, indicates that the majority of integrin β1 containing
heterodimers found on Jurkat cells and human platelets are
in an inactive state. However, in two experiments out of four
we could identify talin-1, which is an adaptor protein that
binds activated integrin β1. This suggests that formaldehyde
cross-linking is a promising tool to study integrin activation
and regulation. In future experiments Jurkat cell lines or
platelets will be stimulated deliberately and the composition
of the integrin β1 complexes will be analyzed. A quantitative12 Journal of Biomedicine and Biotechnology
approach based on SILAC or iTRAQ labelling will then be
applied to distinguish non-activated and activated integrin
β1 and to allow timecourse studies.
By testing diﬀerent formaldehyde concentrations for
cross-linking, we realized that the balance between yield of
cross-linked complex and the loss of protein was shifted in
the case of integrin β1 compared to earlier studies: whereas
0.4% formaldehyde had been established as optimal concen-
tration for studying myc-tagged soluble protein earlier [4],
1%formaldehydeseemedtobemoresuitableforintegrinβ1.
While we used 0.4% formaldehyde for the current studies in
order to minimize artefact generation, higher formaldehyde
concentration may be used for future investigations. Indeed,
varying the formaldehyde concentration is an excellent
means not only to balance yield and protein loss, but also
to distinguish direct and indirect interaction partners of a
protein.
The multistep protocol for the optimization of formalde-
hyde cross-linking described here can be applied to any
protein of interest. While the formaldehyde concentration is
themostimportantvariablethathastobeoptimizedforeach
protein, detection of a formaldehyde cross-linked complex
via western blot analysis simpliﬁes this process. In addition,
the application of antibodies for immunoprecipitations of
modiﬁed proteins has to be monitored carefully, and the
possibility that they do not recognize their antigen anymore
hastobe consideredatalltimes. Ifthese points aretakeninto
account, however, formaldehyde cross-linking paired with
immunoprecipitation will be a very powerful and reliable
method to study protein-protein interactions, especially
weak and transient ones, that can be established as a routine
method in any laboratory.
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